255 related articles for article (PubMed ID: 36661719)
1. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
John A; Spain L; Hamid AA
Curr Oncol; 2023 Jan; 30(1):923-937. PubMed ID: 36661719
[TBL] [Abstract][Full Text] [Related]
2. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
Bellmunt J; Dutcher J
Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
[TBL] [Abstract][Full Text] [Related]
4. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
6. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.
Zoumpourlis P; Genovese G; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Apr; 19(2):103-116. PubMed ID: 33358151
[TBL] [Abstract][Full Text] [Related]
7. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.
Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M
Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397
[TBL] [Abstract][Full Text] [Related]
8. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P; Rioux-Leclercq N; Thibault C; Saldana C; Borchiellini D; Chevreau C; Desmoulins I; Gobert A; Hilgers W; Khalil A; Lemoine N; Schlürmann-Constans F; Négrier S
Cancer Treat Rev; 2021 Jun; 97():102191. PubMed ID: 34015728
[TBL] [Abstract][Full Text] [Related]
9. Advanced treatments in non-clear renal cell carcinoma.
Tazi el M; Essadi I; Tazi MF; Ahellal Y; M'rabti H; Errihani H
Urol J; 2011; 8(1):1-11. PubMed ID: 21404194
[TBL] [Abstract][Full Text] [Related]
10. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
[TBL] [Abstract][Full Text] [Related]
12. [Clinical analysis of non-clear cell renal cell carcinoma].
Ohba K; Asai A; Mitsunari K; Matsuo T; Mochizuki Y; Miyata Y; Sakai H
Hinyokika Kiyo; 2015 Feb; 61(2):43-7. PubMed ID: 25812592
[TBL] [Abstract][Full Text] [Related]
13. Management of Atypical Renal Cell Carcinomas.
Liaw BC; Mehrazin R; Baker C; Sfakianos JP; Tsao CK
Curr Treat Options Oncol; 2017 Sep; 18(10):61. PubMed ID: 28913767
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.
Motzer RJ; Bacik J; Mariani T; Russo P; Mazumdar M; Reuter V
J Clin Oncol; 2002 May; 20(9):2376-81. PubMed ID: 11981011
[TBL] [Abstract][Full Text] [Related]
15. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract][Full Text] [Related]
16. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Albiges L; Molinie V; Escudier B
Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study.
Izumi K; Inoue M; Washino S; Shirotake S; Kagawa M; Takeshita H; Miura Y; Hyodo Y; Oyama M; Kawakami S; Miyagawa T; Saito K; Kageyama Y
Int J Urol; 2023 Sep; 30(9):714-721. PubMed ID: 36541136
[TBL] [Abstract][Full Text] [Related]
18. Advanced Non-Clear Cell Kidney Cancer: In Search of Rational Treatment Approaches.
Ornstein MC; Hutson TE
Cancer J; 2020; 26(5):441-447. PubMed ID: 32947312
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities.
Zarrabi K; Walzer E; Zibelman M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359554
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for non-clear-cell renal cell carcinoma.
David KA; Milowsky MI; Nanus DM
Clin Genitourin Cancer; 2006 Mar; 4(4):263-8. PubMed ID: 16729909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
